Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2B Double Blind, Randomized, Controlled Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of MSP3-LSP Vaccine Candidate Adjuvanted in Aluminium Hydroxide (AIOH) Against Plasmodium Falciparum Clinical Malaria in Healthy Children Aged 12-48 Months in Mali

NCT01341704 is registered in ClinicalTrials.gov with Vac4All as lead sponsor.

NCT NCT01341704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01341704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2B Double Blind, Randomized, Controlled Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of MSP3-LSP Vaccine Candidate Adjuvanted in Aluminium Hydroxide (AIOH) Against Plasmodium Falciparum Clinical Malaria in Healthy Children Aged 12-48 Months in Mali
Lead sponsor
Vac4All
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2011
Completion date
March 31, 2013
Enrollment
800 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria